- Home
- ALDX
as 11-22-2024 4:00pm EST
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 319.4M | IPO Year: | 2014 |
| Target Price: | $10.00 | AVG Volume (30 days): | 571.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.43 - $6.55 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 25.36% |
Latest Aldeyra Therapeutics Inc. News
ALDX Breaking Stock News: Dive into ALDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Top US Penny Stocks To Watch In November 2024
Zacks
5 days ago
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
MT Newswires
6 days ago
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA
Business Wire
6 days ago
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Business Wire
10 days ago
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Zacks
12 days ago
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?
Business Wire
24 days ago
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
MT Newswires
2 months ago
Aldeyra Therapeutics Resubmits New Drug Application for Dry Eye Disease Treatment Candidate
Compare ALDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALDX Aldeyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.